# BPC-157 for Improving Surgical Outcomes and Recovery

## Background: What is BPC-157?

BPC-157 (Body Protection Compound-157) is a pentadecapeptide (15-amino acid) originally isolated from human gastric juice[^1]. It has drawn attention for its remarkable regenerative properties in various tissues. In vitro and animal studies have shown BPC-157 can repair tendons, ligaments, muscles, nerves, bone fractures, and even corneas, and it has aided recovery in models of traumatic brain injury[^1]. These wide-ranging healing effects have earned it nicknames like the “Wolverine peptide” among athletes[^2]. BPC-157 appears to exert its pro-recovery effects by boosting growth factors, promoting angiogenesis (new blood vessel formation), and reducing inflammation, all of which are crucial for tissue repair[^3]. It also modulates neurotransmitter systems involved in pain (e.g., serotonin, dopamine, prostaglandins), potentially providing analgesia without opioids[^4]. Given these properties, there is growing interest in using BPC-157 to enhance post-surgical healing and improve recovery outcomes.

## Preclinical Evidence for Enhanced Healing

Foundational preclinical studies (mostly in rodents) have demonstrated BPC-157’s potent ability to accelerate healing in a variety of injury and surgical models:

- Wound Healing: BPC-157 significantly speeds up the closure of skin wounds. It has been effective in treating surgical incisions, excisions, deep burns, and even diabetic ulcers in animal models[^5]. Treated wounds show faster re-epithelialization, improved collagen deposition, and better tensile strength compared to controls[^5]. Notably, BPC-157’s healing effect is not limited to skin – it tends to generalize to other tissues, suggesting a broad mechanism that can aid healing throughout the body[^6].

- Tendon and Ligament Repair: In a landmark study, Sikiric et al. (2005) showed that BPC-157 could heal a completely transected Achilles tendon in rats within 21 days, without surgical intervention[^7]. The peptide-treated tendons had higher Type-I collagen content, better-organized fiber alignment, and improved biomechanical strength, essentially restoring normal tendon function[^7]. Other tendon/ligament injury models likewise found that BPC-157 treatment leads to stronger and more rapid healing than seen in untreated controls[^8].

- Muscle and Bone Healing: BPC-157 has displayed striking regenerative effects in muscle injuries. For example, a 2025 study surgically detached the quadriceps muscle from the bone in rats (a scenario that normally leads to permanent disability). Rats given oral BPC-157 showed complete reattachment of the muscle to bone with restoration of function[^9][^10]. At various time points, BPC-157–treated animals had the muscle growing back toward the bone, eliminating gaps at the reattachment site, and by 3 months the muscle and bone were effectively re-integrated in a stable, functional union[^9][^10]. In contrast, control rats had healing failure – persistent muscle retraction, a gaping separation, impaired walking, and permanent limb contracture[^9]. Similarly, in fracture and bone-defect models, BPC-157 has improved bone healing and quality[^8], suggesting benefits for orthopedic surgical recovery.

*Figure: MRI cross-sections (T2-weighted) at 3 months post-surgery in a rat model of quadriceps muscle detachment. In BPC-157 treated rats (A,C), the quadriceps muscle is fully reattached to the femur with no gap (red arrows). In contrast, control rats (b,d) show a persistent ~4 mm gap between muscle and bone (yellow arrow), indicating failed healing[^11]. All BPC-157 treated animals achieved complete defect closure and near-normal anatomy, whereas untreated controls had poor healing. This corresponded to restored walking ability in BPC-157 rats versus permanent impairment in controls[^9].*

- Gastrointestinal Healing and Fistulas: BPC-157 was initially noted for its gastroprotective effects, and animal research suggests it can greatly improve healing after GI surgery. In rat models of intestinal anastomosis, BPC-157 accelerated the healing of surgical connections in the bowel[^12]. Most impressively, BPC-157 can heal difficult cases like colocutaneous fistulas, which are abnormal tracts connecting the colon to the skin. In one study, rats with persistent, non-healing fistulas were treated with BPC-157 either orally or by injection. The peptide sped up closure of the colonic and skin defects, leading to full fistula closure (confirmed by macroscopic and biomechanical testing), whereas standard therapies had little effect[^13][^14]. In fact, a corticosteroid (which is sometimes used for inflammatory conditions) worsened the fistulas, but BPC-157 not only counteracted that impairment – it completely resolved the chronic wound[^15][^16]. This highlights BPC-157’s potential to rescue healing even in high-risk scenarios (e.g., patients on steroids or with inflammation).

Overall, these foundational studies show BPC-157 consistently enhances tissue regeneration across skin, muscle, tendon, bone, nerve, and GI tissues. Mechanistically, BPC-157 upregulates pro-healing growth factors (e.g., VEGF) and signaling pathways (ERK, FAK, etc.), promotes angiogenesis and collagen synthesis, and modulates nitric oxide for improved microcirculation[^17][^13]. Importantly, it appears to produce functionally superior healing – repaired tissues exhibit near-normal strength and organization, which is crucial for surgical recovery.

## Evidence from Human Studies

Despite the robust animal data, clinical research in humans is still in early stages. BPC-157 is not yet an approved medication, and thus human studies have been limited in size. However, several pilot trials and case reports have shown promising outcomes for surgical or injury-related recovery:

- Orthopedic (Musculoskeletal) Cases: The largest human series so far is a small 2021 trial of intra-articular BPC-157 injections for chronic knee pain (patients with various knee injuries or degenerative conditions). In this case series, 14 out of 16 patients reported significant knee pain relief after a single BPC-157 injection into the joint, with no reported side effects[^18]. Pain reductions were rapid and clinically meaningful. Furthermore, follow-up suggested that the benefits can be long-lasting – a retrospective analysis found that 7 of 12 patients maintained pain relief for over 6 months after one knee injection[^3]. These results, while from a small unblinded study, indicate that BPC-157 may promote healing or analgesia in joint injuries, hinting at applications for post-surgical orthopedic recovery (e.g., after knee surgeries or rotator cuff repair). Indeed, BPC-157’s efficacy in animal models of tendon/ligament repair supports the idea that post-op joint stability and pain could improve with this peptide. Another report described a weightlifter with a chronic partial tear who experienced accelerated healing when using BPC-157, though such anecdotes await controlled trials.

- Pelvic Surgery / Urologic Inflammation: In 2024, an intriguing pilot study investigated BPC-157 for interstitial cystitis/bladder pain syndrome, a chronic inflammatory condition often refractory to standard treatments. Twelve women with severe interstitial cystitis (and no relief from conventional therapy for over a year) received a single intravesical injection of BPC-157 (directly into the bladder wall). The outcomes were remarkable: 10 of 12 women achieved 100% improvement (complete resolution) of their bladder pain symptoms, and the other 2 women saw about 80% improvement[^19]. This is a striking positive result in a condition that can require surgery (e.g., cystectomy) if conservative management fails. It suggests BPC-157 markedly reduced inflammation and promoted healing of the bladder lining. While interstitial cystitis is not a “surgery,” the study underscores BPC-157’s potential to improve recovery in pelvic floor or genitourinary contexts – for instance, one could envision use after bladder surgeries or to help tissue repair in gynecologic surgical recovery (though formal studies are needed).

- Gastrointestinal (IBD) Trials: BPC-157 (also known by the research code PL14736 or “Bepectin”) advanced to clinical trials for inflammatory bowel disease – conditions often requiring surgery. A Phase I trial in healthy volunteers (42 participants) established that oral BPC-157 up to 9 mg/day for 2 weeks was safe and well-tolerated, with no serious adverse effects[^20]. Subsequently, a multicenter Phase II trial tested BPC-157 rectal enemas in patients with mild-to-moderate ulcerative colitis. Though full results were not published in a journal, conference reports indicated therapeutic benefit: BPC-157 enema was effective in inducing remission of ulcerative colitis compared to placebo in that randomized trial[^21][^22]. Investigators noted BPC-157’s safety and encouraging efficacy in healing colonic mucosa during the active disease[^23]. This provides proof-of-concept that BPC-157 can improve healing in human gastrointestinal tissue – implying potential use in enhancing recovery from intestinal surgeries (e.g., anastomosis healing, fistula closure) in the future. In fact, surgeons have speculated that adding BPC-157 could reduce anastomotic leak rates or help difficult postoperative wounds in the GI tract[^24], since preclinical data showed it safe for that purpose.

- Sports Medicine and Post-Surgical Trials: The medical community is now starting formal trials of BPC-157 in surgical recovery. Ongoing studies (as of 2024–2025) include a single-blinded trial of BPC-157 in patients undergoing knee or shoulder surgery to assess its impact on post-operative recovery[^25]. Another observational trial is examining BPC-157 injections for general injury recovery in patients[^25]. While results are pending, these studies reflect the growing interest in translating BPC-157’s healing effects into the surgical arena. Given the lack of FDA approval, some clinicians have been using it off-label via compounding pharmacies for patients (especially athletes) recovering from surgeries or musculoskeletal injuries[^26]. Anecdotally, orthopedic surgeons have reported cases where difficult-to-heal surgical repairs (like chronic tendon injuries) healed faster with adjunct BPC-157 therapy, though systematic data are lacking. The systematic review literature (through mid-2024) found only one human clinical study on BPC-157’s musculoskeletal use (the knee injection series mentioned above)[^27], underscoring that more high-quality human research is needed even as early results are positive.

## Positive Outcomes and Potential Benefits

All currently reported outcomes with BPC-157 in humans have been positive, with improvements noted in pain relief, functional recovery, and tissue healing – and notably, no significant complications. Based on both the preclinical and preliminary clinical evidence, BPC-157 could offer several benefits for surgical patients:

- Faster Wound and Incision Healing: By promoting collagen production, angiogenesis, and cell proliferation, BPC-157 may speed up the closure of surgical incisions or excisions. Animal studies demonstrated quicker wound epithelialization and stronger wound breaking strength with BPC-157[^5]. For surgical patients, this could translate to reduced healing time, stronger scars, and potentially a lower risk of wound dehiscence or infection.

- Enhanced Repair of Musculoskeletal Tissues: Orthopedic and sports surgeries (rotator cuff repair, ACL reconstruction, tendon transfers, etc.) might particularly benefit. BPC-157 has been shown to improve tendon-to-bone healing (as in the rat Achilles and quadriceps models)[^7][^9]. This suggests it could help surgical grafts or reattachments “take” more robustly. Patients could experience better joint stability and quicker return of function. In fact, the small knee arthritis study indicates patients felt significant pain relief and functional gains in the months following a BPC-157 injection[^18]. For someone recovering from knee surgery, adjunct BPC-157 might similarly reduce pain and swelling, allowing earlier rehabilitation. Its ability to stimulate angiogenesis in low-blood-supply tissues (like ligaments) and increase growth hormone receptors in injured tissue could be a game-changer for notoriously slow-healing surgical repairs[^17][^8].

- Reduced Inflammation and Pain (Opioid-Sparing): Postoperative pain and inflammation are major concerns after surgery. BPC-157’s anti-inflammatory effects (downregulating IL-6, TNF-α, and other cytokines[^17]) can moderate the acute inflammatory response to surgical trauma. Uniquely, BPC-157 may also directly alleviate pain by interacting with pain pathways[^4]. In rodents, it even countered opioid tolerance and withdrawal in studies, hinting at a role in pain modulation[^28][^29]. Clinically, patients who received BPC-157 (knee or bladder studies) reported significant pain reductions without needing additional analgesics[^18][^19]. This raises the possibility that BPC-157 could be an opioid-sparing adjunct after surgery – improving comfort and reducing the need for narcotics[^4][^25]. In the context of the opioid epidemic, a safe peptide that manages post-surgical pain while promoting healing is extremely valuable[^30][^31].

- Better Outcomes in High-Risk or Complex Surgical Cases: Patients with compromised healing (e.g., diabetics, smokers, those on corticosteroids or with autoimmune disease) often face poor surgical outcomes. BPC-157’s broad regenerative effects might tilt the odds in their favor. For instance, steroids normally impede wound healing, but BPC-157 was shown to override steroid-induced healing impairment in burn wounds and other models[^16]. It also healed diabetic ulcers in animals[^32]. This suggests that even in tough conditions (low circulation, ongoing inflammation), BPC-157 can jump-start the healing process. It may prevent complications like anastomotic leaks or fistula formation after gastrointestinal surgery – problems more common in those with Crohn’s or chronic inflammation. The rat fistula study showed BPC-157 achieved closure of fistulas that otherwise persisted indefinitely[^13][^33]. Therefore, surgical patients with comorbidities might especially benefit from BPC-157 to ensure proper healing and reduce the need for re-operations.

- Broad Surgical Applications: Importantly, the potential uses of BPC-157 are not limited to any one type of surgery. The peptide’s effects have been observed in nearly all major organ systems in preclinical research – from healing heart muscle after infarction to nerve regeneration and skin graft integration[^6]. While human data is lacking in many of these domains, it opens the door to exploring BPC-157 in plastic surgery (to reduce scarring and improve graft take), neurosurgery (to aid nerve repair), oral surgery (healing of tooth extractions or jaw surgery, given one study showed it helped heal broken teeth and bone), and gender-affirming surgeries (to promote faster healing of multiple tissue types). The user specifically noted not to limit to any particular group – indeed, BPC-157’s healing properties could in theory help any patient recovering from invasive surgery, whether it’s a top athlete after an ACL repair or a transgender patient recovering from gender confirmation surgery. The key is that all positive outcomes are of interest: wherever tissue needs to heal or recover function, BPC-157 might offer an improvement.

## Safety Profile and Regulatory Status

### Safety

So far, BPC-157 has shown a favorable safety profile in both animals and early human studies. Notably, no toxic dose (LD\_1) could be identified in animal trials, even at very high exposures[^34]. For example, rodents tolerated single injections of 20 mg/kg (orders of magnitude above therapeutic doses) with no ill effects, and dogs given 10 mg/kg also had no adverse reactions[^34]. In formal toxicology assessments, BPC-157 did not damage major organs or alter lab parameters[^34]. This aligns with the Phase I human trial: healthy volunteers given up to 9 mg/day orally for 2 weeks had no significant adverse events, and a recent IV infusion pilot (20 mg over 1 hour) in two adults likewise found no measurable changes in heart, liver, kidney function or vital signs[^35][^36]. Those patients tolerated the infusions without side effects[^35]. In the small clinical studies (knee injection and bladder injection), no side effects or complications were reported[^18][^19]. This lack of observed toxicity is encouraging, especially since many standard treatments (e.g., NSAIDs or steroids) carry significant side effect burdens. Nonetheless, caution is warranted until larger trials confirm safety, as rare adverse events could emerge with wider use.

One theoretical concern is BPC-157’s pro-angiogenic effect: by stimulating blood vessel growth (via VEGF pathways) it could, in theory, promote tumor growth if an undiagnosed cancer is present[^37][^38]. Rapid angiogenesis might also alter normal wound healing balance. So far, a mouse study with cancer cells did not find that BPC-157 made tumors grow dramatically[^38], but this issue underscores the need for cautious patient selection and more research – patients with active cancer should likely avoid BPC-157 until more is known. Another consideration is that BPC-157 is a peptide, so there’s potential (as with any biologic) for immune reactions; however, no allergic or immune-mediated problems have been documented to date.

### Regulatory Status

As of 2025, BPC-157 remains an experimental compound. It is not FDA-approved for any indication, and in many countries it falls into a grey area where it cannot be marketed as a supplement either (since it’s a synthetic peptide, not a dietary ingredient)[^39]. Physicians in the US cannot prescribe it through standard pharmacies, though specialized compounding pharmacies have been known to prepare it for “research use”. Indeed, there is ongoing legal debate about whether compounding pharmacies should be allowed to produce BPC-157 for patients – currently the FDA has it on a “Category 2” list (insufficient safety data) which effectively bans compounding it[^40][^41]. Some clinicians hope the FDA will reconsider if further human trials continue to show safety[^42]. In sports, BPC-157 was temporarily on the World Anti-Doping Agency (WADA) banned list (due to its regenerative capabilities), though it was removed from the banned list by 2022 pending more clarity[^43]. Still, athletes are cautioned to check their sport’s regulations before considering it[^44].

Because of the regulatory limbo, access to BPC-157 is mostly via research supply companies (peptide labs) which sell it “for research purposes only.” This carries quality and legality risks – products may be mislabeled or contaminated. Medical experts strongly advise against obtaining peptides from unregulated sources; if one were to use BPC-157 clinically, the recommendation is to use a verified compounding pharmacy product that has been tested for purity[^40]. Until larger clinical trials establish its efficacy and safety, mainstream surgical protocols will not include BPC-157. Nonetheless, the existing evidence base – albeit from smaller studies – positions BPC-157 as a compelling candidate to improve recovery, meriting the ongoing trials.

## Conclusion and Future Directions

In summary, BPC-157 shows considerable promise for improving surgical outcomes and recovery. It is a unique molecule that appears to accelerate the healing process across many different tissues – essentially boosting the body’s natural repair mechanisms. From orthopedic injuries (where it healed torn tendons and relieved joint pain) to gastrointestinal repairs (where it closed stubborn fistulas and ulcers) and beyond, BPC-157 has demonstrated positive effects in every experimental setting studied. Early human case studies echo these benefits, reporting faster recovery, pain reduction, and successful healing even in hard-to-treat cases[^18][^19]. Equally important, it has shown a strong safety profile in preclinical testing and small trials, without the side effects that often accompany potent healing agents.

That said, it is crucial to recognize that human research is still in its infancy. The best evidence so far comes from animal studies and a handful of small human studies (Level IV/V evidence)[^45], not large randomized trials. To truly know how much BPC-157 can aid surgical patients, we need larger, controlled studies. Such trials are underway for orthopedic surgery recovery[^25], and more are needed in other surgical fields. Researchers will need to determine optimal dosing, timing (e.g., before vs. after surgery), and delivery route (systemic vs. local injection) for each application. They will also monitor for any long-term effects. If these trials confirm the peptide’s benefits, BPC-157 could become a revolutionary adjunct in post-surgical care – improving healing rates, shortening rehabilitation time, and reducing complications like chronic pain or poor wound healing.

In conclusion, BPC-157 represents a novel, multifaceted approach to enhancing recovery from all types of surgery. Its ability to stimulate repair and modulate inflammation/pain could fill an important gap in current surgical medicine. All the positive outcomes observed so far justify the excitement, but also call for rigorous research to move BPC-157 from the realm of “research peptide” to an evidence-based therapy. For now, patients and clinicians should view it as an experimental option – albeit one with extraordinary healing potential. With ongoing studies and growing interest, the coming years will clarify whether BPC-157 can indeed live up to its early promise and become a mainstream tool to improve surgical recovery for diverse patient populations.

Sources: BPC-157 mechanism and sports medicine review[^17][^3]; Pilot human studies (knee pain, bladder pain)[^18][^19]; Preclinical wound and tendon healing studies[^5][^7]; Muscle reattachment study[^9][^10]; Fistula healing study[^13]; Safety and clinical trial references[^34][^21]; Comprehensive reviews[^23][^46].

[^1]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^2]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^3]: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. <https://pubmed.ncbi.nlm.nih.gov/40756949/>
[^4]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^5]: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/>
[^6]: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/>
[^7]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^8]: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. <https://pubmed.ncbi.nlm.nih.gov/40756949/>
[^9]: Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. <https://www.mdpi.com/1999-4923/17/1/119>
[^10]: Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. <https://www.mdpi.com/1999-4923/17/1/119>
[^11]: Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. <https://www.mdpi.com/1999-4923/17/1/119>
[^12]: Journal of Pharmacological Sciences article on BPC-157 (intestinal anastomosis and related models). <https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_pdf>
[^13]: Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System. <https://www.sciencedirect.com/science/article/pii/S1347861319313696>
[^14]: Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System. <https://www.sciencedirect.com/science/article/pii/S1347861319313696>
[^15]: Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System. <https://www.sciencedirect.com/science/article/pii/S1347861319313696>
[^16]: Journal of Pharmacological Sciences article on BPC-157 (effects in corticosteroid-impaired and related models). <https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_pdf>
[^17]: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. <https://pubmed.ncbi.nlm.nih.gov/40756949/>
[^18]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^19]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^20]: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. <https://www.mdpi.com/1424-8247/18/2/185>
[^21]: Journal of Pharmacological Sciences article on BPC-157 (clinical/IBD-related data). <https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_pdf>
[^22]: Journal of Pharmacological Sciences article on BPC-157 (clinical/IBD-related data). <https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_pdf>
[^23]: Journal of Pharmacological Sciences article on BPC-157 (clinical/IBD-related data). <https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_pdf>
[^24]: Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System. <https://www.sciencedirect.com/science/article/pii/S1347861319313696>
[^25]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^26]: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. <https://pubmed.ncbi.nlm.nih.gov/40756949/>
[^27]: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. <https://pubmed.ncbi.nlm.nih.gov/40756949/>
[^28]: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. <https://www.mdpi.com/1424-8247/18/2/185>
[^29]: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. <https://www.mdpi.com/1424-8247/18/2/185>
[^30]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^31]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^32]: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/>
[^33]: Journal of Pharmacological Sciences article on BPC-157 (fistula and related GI models). <https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_pdf>
[^34]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^35]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^36]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^37]: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. <https://www.mdpi.com/1424-8247/18/2/185>
[^38]: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. <https://www.mdpi.com/1424-8247/18/2/185>
[^39]: BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. <https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products>
[^40]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^41]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^42]: Alternative Therapies in Health and Medicine article on BPC-157. <http://www.alternative-therapies.com/oa/pdf/11513.pdf>
[^43]: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. <https://www.mdpi.com/1424-8247/18/2/185>
[^44]: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. <https://pubmed.ncbi.nlm.nih.gov/40756949/>
[^45]: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. <https://pubmed.ncbi.nlm.nih.gov/40756949/>
[^46]: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. <https://www.mdpi.com/1424-8247/18/2/185>
